HRP20170311T1 - Novi spojevi pirolopirimidina kao inhibitori protein kinaza - Google Patents
Novi spojevi pirolopirimidina kao inhibitori protein kinaza Download PDFInfo
- Publication number
- HRP20170311T1 HRP20170311T1 HRP20170311TT HRP20170311T HRP20170311T1 HR P20170311 T1 HRP20170311 T1 HR P20170311T1 HR P20170311T T HRP20170311T T HR P20170311TT HR P20170311 T HRP20170311 T HR P20170311T HR P20170311 T1 HRP20170311 T1 HR P20170311T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- hydrogen
- halo
- hydroxyl
- alkoxy
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 51
- 229910052739 hydrogen Inorganic materials 0.000 claims 42
- 239000001257 hydrogen Substances 0.000 claims 42
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000001475 halogen functional group Chemical group 0.000 claims 26
- 150000002431 hydrogen Chemical class 0.000 claims 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 16
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- -1 hydroxy, methoxy Chemical group 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- UOFYSRZSLXWIQB-UHFFFAOYSA-N abivertinib Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2)C2=N1 UOFYSRZSLXWIQB-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Chemical group 0.000 claims 1
- 239000011737 fluorine Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Claims (18)
1. Spoj s formulom (VIII):
[image]
naznačen time da
X1 je O, NH, S, CH2, ili CF2;
R1 i R2 su neovisno odabrani od vodika, halo, C1-6 alkila, i C1-6 haloalkila;
R3 je odabran od halo, hidroksila, C1-6 alkila, C1-6 alkoksi, cijano, i nitro;
n je broj od nula do 4;
R4 je odabran od vodika, C1-6 alkila, C3-7 cikloalkila, i -NRl2R23; pri čemu je alkil ili cikloalkil nesupstituiran ili supstituiran s hidroksilom ili amino; i svaki R22 i R23 su neovisno odabrani od vodika i C1-6alkila ili R22 i R23 mogu biti spojeni tako da tvore 3 do 10 člani prsten;
R5 je odabran od vodika i C1-6alkila:
R6 je odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C1-6alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
R7 je odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C1-6alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
R8 je odabran od vodika, halo, C1-6alkila, C1-6 haloalkila, C1-6alkoksi C1-6haloalkoksi, hidroksila, cijano. i nitro:
Q je CR9ili N;
gdje je R9 odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C1-6alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
R11 je odabran od vodika i C1-6alkila;
R12 je odabran od vodika i C1-6 alkila;
R13 je odabran od vodika, C1-6 alkila, C1-6acila, SO2C1-6alkila, C3-7cikloalkila, i C6-20 arila, pri čemu svaki alkil ili aril je nesupstituiran ili supstituiran s hidroksilom, C1-6alkoksi, ili halo; i -NR18R19je
[image]
pri čemu Rl0je odabran od vodika i C1-6alkila;
R15 je nesupstituirani metil, ili je C2-4alkil nesupstituiran ili supstituiran s hidroksi, metoksi, ili halo; i m je 1 ili 2; ili je
(b) gdje su R19 i R9 uzeti zajedno tako da tvore 5- ili 6-člani heteroarilni prsten proizvoljno supstituiran s C1-6alkilom koji je nesupstituiran ili supstituiran s amino, hidroksilom, ili halo; i R18 je vodik ili C1-6alkil, ili nije prisutan da se zadovolji valencija heteroarilnog prstena; pod uvjetom da niti jedan od R6 ili R7 je metoksi kada -NRI8R19 je
[image]
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1, naznačen time da spoj je spoj s formulom (Ia) ili (Ib):
[image]
[image]
pri čemu
R1 i R2 su neovisno odabrani od vodika, halo, C1-6alkila, i C1-6haloalkila;
R3 je odabran od halo, hidroksila, C1-6alkila, C1-6 alkoksi, cijano, i nitro;
n je broj od nula do 4;
R4 je odabran od vodika, C1-6alkil, C3-7 cikloalkil, i -NR22R23;
pri čemu alkil ili cikloalkil je nesupstituiran ili supstituiran s hidroksilom ili amino; i
svaki R22 i R23 su neovisno odabrani od vodika i C1-6alkila ili R22 i R23 mogu biti spojeni tako da tvore 3 do 10 člani prsten;
R5 je odabran od vodika i C1-6alkila;
R6 je odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C2-6 alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
R7 je odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C2-6alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
R8 je odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C1-6alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
Q je CR9ili N;w
ovdje je R9 odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C1-6alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
R10 je odabran od vodika i C1-6alkila;
a je jedan ili dva;
prsten A je aromatski prsten;
R20 i R21 su neovisno odabrani od vodika i C1-6alkila;
pri čemu alkil je nesupstituiran ili supstituiran s amino, hidroksilom, ili halo;
pri čemu R21 može biti odsutan ako je potrebno da se zadovolji valencija;
R11 je odabran od vodika i C1-6alkila;
R12 je odabran od vodika i C1-6 alkil; i
R13 je odabran od vodika, C1-6alkila, C1-6acila, SO2- C1-6alkila, C3-7cikloalkila, i C6-20 arila,
pri čemu svaki alkil ili aril je nesupstituiran ili supstituiran s hidroksilom, C1-6alkoksi, ili halo;
ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema zahtjevu 1, naznačen time da spoj je spoj s formulom (II):
[image]
pri čemu
R1 i R2 su neovisno odabrani od vodika, halo, C1-6alkila, i C1-6haloalkila;
R3 je odabran od halo, hidroksila, C1-6alkila, C1-6alkoksi, cijano, i nitro;
N je broj od nula do 4;
R4 je odabran od vodika, C1-6alkil, C3-7 cikloalkil, i -NR22R23;
pri čemu alkil ili cikloalkil je nesupstituiran ili supstituiran s hidroksilom ili amino; i
svaki R22 i R23 su neovisno odabrani od vodika i C1-6 alkila ili R22 i R23 mogu biti spojeni tako da tvore 3 do 10 člani prsten;
R3 je odabran od vodika i C1-6alkila;
R6 je odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C2-6 alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
R7 je odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C2-6 alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
R8 je odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C1-6alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
Q je CR9ili N;
gdje je R9 odabran od vodika, halo, C1-6alkila, C1-6haloalkila, C1-6alkoksi, C1-6haloalkoksi, hidroksila, cijano, i nitro;
R10 je odabran od vodika i C1-6alkila;
R11 je odabran od vodika i C1-6alkila;
R12 je odabran od vodika i C1-6 alkila; i
R13 je odabran od vodika, C1-6alkila, i C6-20 arila, pri čemu svaki alkil ili aril je nesupstituiran ili supstituiran s hidroksilom, C1-6alkoksi, ili halo;
ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema zahtjevu 1, naznačen time da X1 je O ili NH.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time da R1 i R2 su svaki vodik.
6. Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time da n je nula.
7. Spoj prema zahtjevu 1, naznačen time da -NR18R19 je
[image]
8. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time da R10 je metil.
9. Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time da Q je CR9.
10. Spoj prema zahtjevu 9, naznačen time da R9 je vodik ili fluor.
11. Spoj prema zahtjevu 1, naznačen time daje spoj odabran iz skupine koja sadrži
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i njihove farmaceutski prihvatljive soli.
12. Spoj prema zahtjevu 1, naznačen time da spoj je spoj s formulom (VII):
[image]
pri čemu
R1 i R2 su neovisno odabrani iz niza koji čine vodik, halo, C1-6alkil, i C1-6haloalkil;
R8 je odabran iz niza koji čine halo, C1-6alkil, C1-6haloalkil, C1-6alkoksi, C1-6haloalkoksi, hidroksil, cijano, i nitro;
R10je C1-6alkil; i
Rl3je vodik ili C1-6alkil; ili njegova farmaceutski prihvatljiva sol.
13. Farmaceutski pripravak, naznačen time da sadrži (a) barem jedan spoj prema bilo kojem od zahtjeva 1 do 12 ili njegovu farmaceutski prihvatljivu sol, te (b) farmaceutski prihvatljiv nosač ili pomoćnu tvar.
14. Spoj prema bilo kojem od zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak prema zahtjevu 13, naznačen time da je za uporabu za liječenje ili sprječavanje poremećaja proliferacije, raka, tumora, upalne bolesti, autoimune bolesti, psorijaze, bolesti suhog oka ili imunološki srodne bolesti.
15. Spoj ili farmaceutski pripravak za uporabu prema zahtjevu 14, naznačen time daje poremećaj proliferacije odabran iz skupine koju čine sarkom, epidermoidni rak, fibrosarkom, karcinom vrata maternice, karcinom želuca, rak kože, leukemija, limfom, karcinom pluća, rak pluća ne-malih stanica, rak debelog crijeva, rak središnjeg živčanog sustava, melanom, rak jajnika, rak bubrega, rak prostate, rak dojke, rak jetre, karcinom glave i vrata, te rak gušterače.
16. Spoj prema zahtjevu 1, naznačen time da spoj je N-(3-((2-((3-fluor-4-(4-metilpiperazin--il) fenil) amino)- 7H-pirolo[2,3-d]pirimidin-4-il)oksi)fenil)akrilamid ili njegova farmaceutski prihvatljiva sol.
17. Spoj prema zahtjevu 16, naznačen time da spoj je hidrokloridna sol ili maleatna sol N-(3-((2-((3-fluor-4- (4-metilpiperazin-1-il)fenil)amino)-7H-pirolo[2,3-d]pirimidin-4-il)oksi)fenil)akrilamida.
18. Kombinacija spoja prema bilo kojem od zahtjeva 1 do 12, ili njegove farmaceutski prihvatljive soli, i drugog profilaktičkog ili terapijskog sredstva naznačena time daje za uporabu za liječenje ili sprječavanje poremećaja proliferacije, raka, tumora, upalne bolesti, autoimune bolesti, psorijaze, bolesti suhog oka ili imunološki srodne bolesti kod subjekta.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680231P | 2012-08-06 | 2012-08-06 | |
| US13/843,554 US9034885B2 (en) | 2012-01-13 | 2013-03-15 | EGFR modulators and uses thereof |
| US201361814147P | 2013-04-19 | 2013-04-19 | |
| US13/917,514 US8685988B2 (en) | 2012-08-06 | 2013-06-13 | EGFR modulators and uses thereof |
| EP13745491.4A EP2880035B9 (en) | 2012-08-06 | 2013-07-11 | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
| PCT/US2013/050163 WO2014025486A1 (en) | 2012-08-06 | 2013-07-11 | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170311T1 true HRP20170311T1 (hr) | 2017-04-21 |
Family
ID=50068479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170311TT HRP20170311T1 (hr) | 2012-08-06 | 2017-02-23 | Novi spojevi pirolopirimidina kao inhibitori protein kinaza |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP2880035B9 (hr) |
| JP (2) | JP6215938B2 (hr) |
| KR (1) | KR102181365B1 (hr) |
| CN (2) | CN107266453B (hr) |
| AU (1) | AU2013300106B2 (hr) |
| BR (1) | BR112015002709B1 (hr) |
| CA (1) | CA2881275C (hr) |
| CY (1) | CY1120844T1 (hr) |
| DK (1) | DK2880035T3 (hr) |
| ES (2) | ES2618007T3 (hr) |
| HK (1) | HK1210471A1 (hr) |
| HR (1) | HRP20170311T1 (hr) |
| HU (1) | HUE031955T2 (hr) |
| IN (1) | IN2015DN00914A (hr) |
| LT (1) | LT2880035T (hr) |
| MX (1) | MX361992B (hr) |
| NZ (1) | NZ629807A (hr) |
| PT (1) | PT2880035T (hr) |
| RU (2) | RU2018104702A (hr) |
| SG (1) | SG11201500872SA (hr) |
| WO (1) | WO2014025486A1 (hr) |
| ZA (2) | ZA201500762B (hr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| US10799504B2 (en) | 2012-01-13 | 2020-10-13 | ACEA Therapeutics, Inc. | Heterocyclic compounds and uses as anticancer agents |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| SG11201505446WA (en) | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| WO2014151871A2 (en) * | 2013-03-14 | 2014-09-25 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
| CN105916851A (zh) * | 2013-07-11 | 2016-08-31 | 艾森生物科学公司 | 嘧啶衍生物作为激酶抑制剂 |
| WO2015127234A1 (en) * | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| KR20170024120A (ko) | 2014-07-14 | 2017-03-06 | 시그날 파마소티칼 엘엘씨 | 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물 |
| CA2976109A1 (en) | 2015-02-13 | 2016-08-18 | Dana-Farber Cancer Institute, Inc. | Substituted pyrrolopyrimidine, pyrazolopyrimidine and purine derivatives and use thereof as lrrk2 inhibitors |
| JP2018104290A (ja) * | 2015-04-28 | 2018-07-05 | アステラス製薬株式会社 | ピラジンカルボキサミド化合物を有効成分とする医薬組成物 |
| WO2016173438A1 (zh) * | 2015-04-29 | 2016-11-03 | 南京明德新药研发股份有限公司 | 稠环或三环芳基嘧啶化合物用作激酶抑制剂 |
| WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| CN107949388B (zh) | 2015-10-09 | 2021-10-26 | 艾森医药公司 | 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法 |
| CN105646496B (zh) * | 2016-01-20 | 2018-07-20 | 华侨大学 | 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用 |
| CN107540661A (zh) * | 2016-06-24 | 2018-01-05 | 正大天晴药业集团股份有限公司 | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 |
| CN107663208B (zh) * | 2016-07-27 | 2021-10-15 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的药用盐及其制备方法与用途 |
| CN107663207B (zh) * | 2016-07-27 | 2021-07-30 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法 |
| CN107955019B (zh) * | 2016-10-17 | 2021-09-14 | 广东众生药业股份有限公司 | 一种egfr抑制剂的盐型、晶型及其制备方法 |
| CN106749266B (zh) * | 2016-11-14 | 2019-01-22 | 山东大学 | 吡咯并[2,3-d]嘧啶类化合物的高效制备方法 |
| CN108299419B (zh) * | 2017-01-11 | 2022-04-26 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 |
| JP7164203B2 (ja) | 2017-02-08 | 2022-11-01 | 中国医▲薬▼研究▲開▼▲発▼中心有限公司 | ピロロ芳香族複素環化合物及びその製造方法並びに医薬用途 |
| CN111212837A (zh) * | 2017-04-07 | 2020-05-29 | 艾森医药公司 | 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法 |
| CN109422751B (zh) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 |
| US11709156B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved analytical analysis |
| US11709155B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes |
| AU2018394997B2 (en) * | 2017-12-28 | 2021-02-04 | Daewoong Pharmaceutical Co., Ltd. | Oxy-fluoropiperidine derivative as kinase inhibitor |
| KR102577242B1 (ko) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| KR102577241B1 (ko) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| WO2019195753A1 (en) | 2018-04-05 | 2019-10-10 | Tolero Pharmaceuticals, Inc. | Axl kinase inhibitors and use of the same |
| CA3095580A1 (en) | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
| JP2021530554A (ja) | 2018-07-26 | 2021-11-11 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 異常なａｃｖｒ１発現を伴う疾患を処置するための方法およびそこで使用するためのａｃｖｒ１阻害剤 |
| EP3613738A1 (en) * | 2018-08-23 | 2020-02-26 | Lead Discovery Center GmbH | 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer |
| AU2020221247A1 (en) | 2019-02-12 | 2021-08-05 | Sumitomo Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| CN111747950B (zh) * | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
| CN110407840A (zh) * | 2019-08-15 | 2019-11-05 | 重庆化工职业学院 | 一种艾维替尼的制备方法 |
| JP7473642B2 (ja) * | 2019-11-13 | 2024-04-23 | ジャージアン・ロングチャーム・バイオ－テック・ファーマ・カンパニー・リミテッド | Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用 |
| US11918936B2 (en) | 2020-01-17 | 2024-03-05 | Waters Technologies Corporation | Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding |
| WO2021147952A1 (zh) * | 2020-01-21 | 2021-07-29 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| CN111848631B (zh) * | 2020-08-28 | 2022-04-19 | 四川大学华西医院 | 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN114957248B (zh) * | 2022-05-09 | 2023-12-29 | 南开大学 | 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用 |
| CN115611989B (zh) * | 2022-10-09 | 2023-08-01 | 武汉理工大学 | 机械活化淀粉衍生物抑制剂的优化制备方法及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563905A (en) | 1992-09-24 | 1996-10-08 | Hughes Aircraft Company | Network communication system having time-sliced protocol |
| US7560269B2 (en) | 2002-12-20 | 2009-07-14 | Acea Biosciences, Inc. | Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays |
| US7468255B2 (en) | 2002-12-20 | 2008-12-23 | Acea Biosciences | Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology |
| US7732127B2 (en) | 2002-12-20 | 2010-06-08 | Acea Biosciences, Inc. | Dynamic monitoring of cell adhesion and spreading using the RT-CES system |
| US7470533B2 (en) | 2002-12-20 | 2008-12-30 | Acea Biosciences | Impedance based devices and methods for use in assays |
| AU2003267998A1 (en) | 2002-07-20 | 2004-02-09 | Acea Biosciences, Inc. | Impedance based devices and methods for use in assays |
| CA2550274A1 (en) | 2003-11-12 | 2005-05-26 | Acea Biosciences, Inc. | Real time electronic cell sensing systems and applications for cell-based assays |
| ES2381962T3 (es) * | 2005-09-21 | 2012-06-04 | 4Sc Ag | Nuevos sulfonilpirroles como inhibidores de las HDAC |
| EP2440559B1 (en) * | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
| WO2011079231A1 (en) * | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
-
2013
- 2013-07-11 JP JP2015526540A patent/JP6215938B2/ja active Active
- 2013-07-11 AU AU2013300106A patent/AU2013300106B2/en active Active
- 2013-07-11 RU RU2018104702A patent/RU2018104702A/ru not_active Application Discontinuation
- 2013-07-11 EP EP13745491.4A patent/EP2880035B9/en active Active
- 2013-07-11 IN IN914DEN2015 patent/IN2015DN00914A/en unknown
- 2013-07-11 EP EP16202341.0A patent/EP3170825B1/en active Active
- 2013-07-11 RU RU2015107831A patent/RU2645672C2/ru active
- 2013-07-11 NZ NZ629807A patent/NZ629807A/en not_active IP Right Cessation
- 2013-07-11 ES ES13745491.4T patent/ES2618007T3/es active Active
- 2013-07-11 LT LTEP13745491.4T patent/LT2880035T/lt unknown
- 2013-07-11 PT PT137454914T patent/PT2880035T/pt unknown
- 2013-07-11 KR KR1020157006007A patent/KR102181365B1/ko active IP Right Grant
- 2013-07-11 MX MX2015001715A patent/MX361992B/es active IP Right Grant
- 2013-07-11 CN CN201710229308.7A patent/CN107266453B/zh active Active
- 2013-07-11 BR BR112015002709-1A patent/BR112015002709B1/pt active IP Right Grant
- 2013-07-11 ES ES16202341T patent/ES2733576T3/es active Active
- 2013-07-11 SG SG11201500872SA patent/SG11201500872SA/en unknown
- 2013-07-11 DK DK13745491.4T patent/DK2880035T3/en active
- 2013-07-11 CA CA2881275A patent/CA2881275C/en active Active
- 2013-07-11 WO PCT/US2013/050163 patent/WO2014025486A1/en active Application Filing
- 2013-07-11 CN CN201380001359.4A patent/CN103748096B/zh active Active
- 2013-07-11 HU HUE13745491A patent/HUE031955T2/en unknown
-
2015
- 2015-02-02 ZA ZA2015/00762A patent/ZA201500762B/en unknown
- 2015-11-16 HK HK15111282.7A patent/HK1210471A1/xx unknown
-
2016
- 2016-01-29 ZA ZA2016/00648A patent/ZA201600648B/en unknown
-
2017
- 2017-01-17 JP JP2017005935A patent/JP2017061581A/ja not_active Withdrawn
- 2017-02-23 HR HRP20170311TT patent/HRP20170311T1/hr unknown
- 2017-03-02 CY CY171100274T patent/CY1120844T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170311T1 (hr) | Novi spojevi pirolopirimidina kao inhibitori protein kinaza | |
| HRP20200624T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka | |
| MY172110A (en) | Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| HRP20180746T4 (hr) | Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze | |
| HRP20171748T1 (hr) | 6-amino kinazolina ili 3-cijano derivati kinolina, postupci priprave i njihova farmaceutska uporaba | |
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| JP2014139226A5 (hr) | ||
| PE20161246A1 (es) | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo | |
| EA201391239A1 (ru) | Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ | |
| EA201390199A1 (ru) | 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение | |
| HRP20171999T1 (hr) | Novi derivati aminopirimidina | |
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| HRP20161074T1 (hr) | Benzoksazolski inhibitori kinaza i postupci njihove upotrebe | |
| MY163791A (en) | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS cFMS INHIBITORS | |
| EA201490016A1 (ru) | Комбинация панобиностата и руксолитинаба при лечении рака, такого как миелопролиферативное новообразование | |
| EA201492125A1 (ru) | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 | |
| JP2014503567A5 (hr) | ||
| HRP20201211T1 (hr) | Derivat dihidropiridazin-3,5-diona | |
| HRP20120762T1 (hr) | Tetrasupstituirani piridazini kao inhibitori hedgehog puta | |
| JP2009536620A5 (hr) | ||
| HRP20140481T1 (hr) | SUPSTITUIRANI SPOJEVI IMIDAZO[1,2-b]PIRIDAZINA KAO INHIBITORI TRK KINAZE | |
| JP2015510886A5 (hr) | ||
| EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы |